Acumen Pharmaceuticals (ABOS) Stock Forecast, Price Target & Predictions
ABOS Stock Forecast
Acumen Pharmaceuticals stock forecast is as follows: an average price target of $7.00 (represents a 169.23% upside from ABOS’s last price of $2.60) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
ABOS Price Target
The average price target for Acumen Pharmaceuticals (ABOS) is $7.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $7.00. This represents a potential 169.23% upside from ABOS's last price of $2.60.
ABOS Analyst Ratings
According to 6 Wall Street analysts, Acumen Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ABOS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (66.67%), 2 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Acumen Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | David Hoang | Citigroup | $7.00 | $3.41 | 105.28% | 169.23% |
The latest Acumen Pharmaceuticals stock forecast, released on Jul 25, 2024 by David Hoang from Citigroup, set a price target of $7.00, which represents a 105.28% increase from the stock price at the time of the forecast ($3.41), and a 169.23% increase from ABOS last price ($2.60).
Acumen Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $7.00 | $7.00 |
| Last Closing Price | $2.60 | $2.60 | $2.60 |
| Upside/Downside | -100.00% | 169.23% | 169.23% |
In the current month, the average price target of Acumen Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Acumen Pharmaceuticals's last price of $2.60. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 25, 2024 | Citigroup | - | Buy | Initialise |
| May 18, 2023 | Jefferies | - | Hold | Initialise |
| May 18, 2023 | Seaport Global | - | Buy | Initialise |
| May 18, 2023 | BTIG | - | Buy | Initialise |
| May 18, 2023 | Canaccord Genuity | - | Buy | Initialise |
| May 18, 2023 | Scotiabank | - | Sector Perform | Initialise |
Acumen Pharmaceuticals's last stock rating was published by Citigroup on Jul 25, 2024. The company Initialise its ABOS rating from "null" to "Buy".
Acumen Pharmaceuticals Financial Forecast
Acumen Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | $15.00M |
| High Forecast | - | - | - | - | - | - | - | $15.00M |
| Low Forecast | - | - | - | - | - | - | - | $15.00M |
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 |
| Surprise % | - | - | - | - | - | - | - | - |
Acumen Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ABOS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Acumen Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 |
| EBITDA | - | - | - | - | - | - | - | $-18.45M |
| Avg Forecast | - | - | - | - | - | - | - | $3.00M |
| High Forecast | - | - | - | - | - | - | - | $3.00M |
| Low Forecast | - | - | - | - | - | - | - | $3.00M |
| Surprise % | - | - | - | - | - | - | - | -6.15% |
undefined analysts predict ABOS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Acumen Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Acumen Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 |
| Net Income | - | - | - | - | - | - | - | $-16.50M |
| Avg Forecast | $-27.04M | $-27.64M | $-26.44M | $-25.23M | $-23.51M | $-21.73M | $-16.82M | $-16.45M |
| High Forecast | $-27.04M | $-27.64M | $-26.44M | $-25.23M | $-23.51M | $-15.09M | $-16.82M | $-13.61M |
| Low Forecast | $-27.04M | $-27.64M | $-26.44M | $-25.23M | $-23.51M | $-27.77M | $-16.82M | $-19.28M |
| Surprise % | - | - | - | - | - | - | - | 1.00% |
Acumen Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ABOS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Acumen Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 |
| SG&A | - | - | - | - | - | - | - | $5.15M |
| Avg Forecast | - | - | - | - | - | - | - | $13.46M |
| High Forecast | - | - | - | - | - | - | - | $13.46M |
| Low Forecast | - | - | - | - | - | - | - | $13.46M |
| Surprise % | - | - | - | - | - | - | - | 0.38% |
Acumen Pharmaceuticals's average Quarter SG&A projection for Jun 24 is -, based on 1 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ABOS last annual SG&A of $5.15M (Dec 23).
Acumen Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 |
| EPS | - | - | - | - | - | - | - | $-0.28 |
| Avg Forecast | $-0.45 | $-0.46 | $-0.44 | $-0.42 | $-0.39 | $-0.36 | $-0.28 | $-0.27 |
| High Forecast | $-0.45 | $-0.46 | $-0.44 | $-0.42 | $-0.39 | $-0.25 | $-0.28 | $-0.23 |
| Low Forecast | $-0.45 | $-0.46 | $-0.44 | $-0.42 | $-0.39 | $-0.46 | $-0.28 | $-0.32 |
| Surprise % | - | - | - | - | - | - | - | 1.02% |
According to undefined Wall Street analysts, Acumen Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ABOS previous annual EPS of $NaN (undefined).
Acumen Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
ABOS Forecast FAQ
Is Acumen Pharmaceuticals a good buy?
Yes, according to 6 Wall Street analysts, Acumen Pharmaceuticals (ABOS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 66.67% of ABOS's total ratings.
What is ABOS's price target?
Acumen Pharmaceuticals (ABOS) average price target is $7 with a range of $7 to $7, implying a 169.23% from its last price of $2.6. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Acumen Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for ABOS stock, the company can go up by 169.23% (from the last price of $2.6 to the average price target of $7), up by 169.23% based on the highest stock price target, and up by 169.23% based on the lowest stock price target.
Can Acumen Pharmaceuticals stock reach $4?
ABOS's average twelve months analyst stock price target of $7 supports the claim that Acumen Pharmaceuticals can reach $4 in the near future.
What are Acumen Pharmaceuticals's analysts' financial forecasts?
Acumen Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-62.055M (high $-55.414M, low $-68.091M), average SG&A $0 (high $0, low $0), and average EPS is $-1.033 (high $-0.922, low $-1.133). ABOS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-106M (high $-106M, low $-106M), average SG&A $0 (high $0, low $0), and average EPS is $-1.77 (high $-1.77, low $-1.77).